Walleye Capital
KYTX icon

Walleye Capital’s Kyverna Therapeutics KYTX Stock Holding History

Walleye Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
245,587
+207,391
+543% +$1.84M 0.01% 1440
2026
Q1 		$330K Buy
+38,196
New +$318K ﹤0.01% 2996
2024
Q3 		– Sell
-156,515
Closed -$1.17M – 5959
2024
Q2 		$1.17M Buy
156,515
+6,515
+4% +$99.5K ﹤0.01% 2669
2024
Q1 		$3.73M Buy
+150,000
New +$4.19M 0.01% 1525

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Walleye Capital's KYTX Position: Q2 2026 in Review

Walleye Capital increased its Kyverna Therapeutics (KYTX) stake by 543% in Q2 2026, buying an estimated $1.84M and bringing the position to 245,587 shares worth $2.19M. The position accounts for 0.01% of the portfolio, ranked #1440.

Walleye Capital first reported a position in KYTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $3.73M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Walleye Capital held 245,587 shares of Kyverna Therapeutics worth $2.19M as of Q2 2026.
  • Walleye Capital bought 207,391 Kyverna Therapeutics shares in Q2 2026, an estimated $1.84M.
  • Kyverna Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1440 holding.
  • Walleye Capital first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Walleye Capital's Kyverna Therapeutics position peaked at $3.73M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.